20th Annual BioPartnering FutureEUROPE™
The Square | Brussels, Belgium
7-9 October 2012
![]() |
20th Annual BioPartnering FutureEUROPE™ 7-9 October 2012 |
||
Overview
We have been serving the needs of the European life science industry for 20 years. We have had great success in London as BioPartnerng Europe™ (BPFE), and now after evolving into BioPartnering Future EUROPE (BPFE) we see this new conference becoming the number one global platform in Europe for partnerships and dealmaking. BPFE is the next step in networking the European life science industry, a truly "Pan-European" event, which means all of the European bioeconomy in one place.
What makes BPFE different from other events?BPFE is about quality. We help make business happen, enabling partnering, and working together to Get A Deal. We are about providing ample time and access to Pharma, Venture Capitalists, and emerging Biotech companies for business opportunities and strategic partnerships to launch.
The Belgium ConsortiumBPFE is designed using a consortium approach to bring together Europe's leaders: leading biopharma companies, leading C-level executives; leaders from the investment world, from government and from scientific research. For 2012 TVG is working closely with the Belgium Consortium, to implement the strategic vision of this new conference.
The evolution of evolving:The question has been asked, "Why are we leaving the UK?" The answer, our project is to use BPFE to encompass all of Europe. We aim to accomplish this by moving the event around to enable building more successful relationships with Europeans and access more partnering opportunities. The Future:How do we see the future of European Life Sciences? The European Commission and EuropaBio have specific and detailed plans for the development of the life sciences as a centerpiece of the European knowledge-economy by 2020. BPFE is intended to help achieve these goals. BPFE is an opportunity for you to be heard and to lend your voice to advancing Europe’s life science industry to address the issues that impact the well being of all Europe’s citizens and to build European life science competitiveness in a global market. |
||
|
||||
|
CONNECT: |
||||